Systemic Antifungal Therapy
Amphotericin B (AmB) (n=8, 24%) was the empirical antifungal treatment
of choice until 2010, when it was replaced mainly by liposomal
amphotericin B (ambisome) (n=13, 38%). Novel antifungals, posaconazole
and isavuconazole, have been employed as additional treatment options in
our institution since 2008 and 2017, respectively. Antifungal treatment
was adjusted following the identification of infectious agent.